Temporal trends and risk factors for extended-spectrum beta-lactamase-producing \textit{Escherichia coli} in adults with catheter-associated urinary tract infections

Joseph T Spadafino\textsuperscript{1}, Bevin Cohen\textsuperscript{1,2*}, Jianfang Liu\textsuperscript{2} and Elaine Larson\textsuperscript{1,2}

Abstract

\textbf{Background:} Extended-spectrum beta-lactamase (ESBL)-producing \textit{Escherichia coli} cause up to 10\% of catheter-associated urinary tract infections (CAUTI). We report changes in ESBL prevalence among CAUTIs in an adult acute care hospital from 2006-2012 and describe factors associated ESBL-production among \textit{E. coli} CAUTI.

\textbf{Findings:} Data on patients $\geq$ 18 years discharged from a 647-bed tertiary/quaternary care hospital (2006-2012), a 221-bed community hospital (2007-2012), and a 914-bed tertiary/quaternary care hospital (2008) were obtained retrospectively from an electronic database (N = 415,430 discharges). Infections were identified using a previously validated electronic algorithm. Information on medical conditions and treatments were collected from electronic health records and discharge billing codes. A case-control design was used to determine factors associated with having a CAUTI caused by an ESBL-producing \textit{E. coli} versus a non-ESBL-producing \textit{E. coli}. Changes in yearly proportion of ESBL \textit{E. coli} CAUTI at the 647-bed tertiary/quaternary care hospital were evaluated. ESBL increased from 4\% in 2006 to 14\% in 2012, peaking at 18\% in 2009. Prior antibiotic treatment and urinary tract disease significantly increased odds of ESBL.

\textbf{Conclusions:} This study provides evidence that treatment with beta-lactam and non-beta-lactam antibiotics is a risk factor for acquiring ESBL-producing \textit{E. coli} CAUTI, and the prevalence of this organism may be increasing in acute care hospitals.

\textbf{Keywords:} Catheter-associated urinary tract infections, Extended-spectrum beta-lactamase-producing \textit{Escherichia coli}, Antimicrobial resistance

Introduction

\textit{Escherichia coli} is the most common causative agent of catheter-associated urinary tract infections (CAUTI; $\geq$20\%) [1]. Extended-spectrum beta-lactamase (ESBL)-producing strains of \textit{E. coli}, while representing a small percentage (<10\%), are particularly concerning because they confer resistance to a myriad of antibiotics including penicillins and third generation cephalosporins, and because their prevalence has been increasing in community and hospital settings during recent years [2,3]. The purpose of this study is to describe changes in prevalence and factors associated with CAUTI caused by ESBL-producing \textit{E. coli} in three adult acute care hospitals from 2006 through 2012.

Methods

Data on all patients $\geq$18 years discharged from three New York City hospitals within a single network were obtained retrospectively from a larger electronic database as part of an NIH-funded study (Distribution of the Costs of Antimicrobial Resistant Infections, NR010822). The study was approved by the Institutional Review Board of Columbia University Medical Center. Data were available from 2006-2012 for a 647-bed tertiary/quaternary care hospital, from 2007-2012 for a 221-bed community hospital, and from 2008 for a 914-bed tertiary/quaternary care hospital.
Results of the case control study are presented in Table 1. In the crude analyses, cases were significantly older than controls (70.4 and 67.5 years, respectively) and had greater Charlson Comorbidity scores (7.06 and 6.44, respectively). Male sex, preexisting urinary tract disease, having a urinary tract procedure, and longer duration of catheterization prior to CAUTI onset were also associated with increased odds of ESBL production. Receiving any antibiotic prior to CAUTI onset was significantly associated with ESBL production, and six antibiotics specifically were administered significantly more often in cases than in controls: aminoglycosides, first-generation cephalosporins, third-generation cephalosporins, macrolides, fourth-generation penicillins, and vancomycin. In the multivariable model, age, urinary tract disease, and receipt of aminoglycosides, first-generation cephalosporins, macrolides, fourth-generation penicillins, and vancomycin were significantly associated with ESBL production.

Discussion

Though several studies have examined risk factors for ESBL emergence in hospitalized and non-hospitalized patients with urinary tract infections (UTI), these studies were community-based and not focused on catheterized patients [2,3,6-8]. Since CAUTI may result in antibiotic susceptibility patterns different from those of non-catheter-related UTI, understanding the prevalence trends and risk factors for ESBL emergence unique to this population is important for the development and implementation of effective prevention efforts [9]. The prevalence of ESBL-producing strains in this sample (12.2%) was slightly higher than reported in previous studies which included both catheterized and non-catheterized patients (7-10.9%) [6,7,10], but the overall increase in ESBL prevalence over time is consistent with other reports [2,3,10]. An analysis of trends in gram-negative bacterial resistance among patients with UTI from a nationally representative sample of US hospitals between 2000 and 2009 found a
threefold increase in cases of ESBL-producing *E. coli*, similar to our results [3].

Our findings regarding risk factors for ESBL production are also similar to those reported in previous studies that included community-acquired UTIs and/or non-catheter-associated hospital-acquired UTIs. In our sample of hospitalized, catheterized patients, we found a strong positive association between prior treatment with beta-lactam and non-beta-lactam antibiotics and ESBL production, consistent with other studies of UTI caused by *E. coli* [2,6,8]. Like most other studies, we failed to detect significant differences in odds of ESBL by age, gender, comorbid conditions, and overall severity of illness; however we did find a significant positive association with urinary tract disease [6-8,10]. Patients who undergo a urinary tract procedure or surgery may be at greater risk for the emergence of resistance due in part to longer catheterization periods and increased antibiotic use. Nevertheless, urinary tract disease remained significant even after adjustment for length of catheterization and treatment with antibiotics, suggesting that it may have an independent association with ESBL.

While this is one of the largest studies to focus on CAUTI with ESBL-producing *E. coli* and document trends in resistance over time, the research does have some limitations. First, this study makes use of electronically available data to identify infections, as well as to determine patients’ clinical risk factors and comorbid health conditions. Information on preexisting health conditions was garnered from medical billing data, which are not collected for the purposes of research and may have low sensitivity and/or specificity. Aside from potential misclassification, using electronic data also prohibited us from reporting detailed information on the resistance patterns exhibited by the isolates. In addition, data on antimicrobial use was limited to those prescribed during the patients’ hospitalizations. The case-control study was restricted to three hospitals within a single, geographically narrow network, possibly limiting generalizability. Additionally, we were only able to investigate trends over time at one hospital due to limited data

| Variable | ESBL-producing *E. coli* isolates (N = 271) | Non-ESBL-producing *E. coli* isolates (N = 1893) | Total (N = 2164) | Bivariable analysis p-value | Multivariable analysis Odds Ratio (95% CI) |
|----------|---------------------------------|---------------------------------|----------------|--------------------------|---------------------------------|
| Mean (range) age, in years | 70.4 (24-98) | 67.5 (18-103) | 67.9 (18-103) | *0.003* | 1.01 (1.00, 1.02) |
| Gender (reference, female) | | | | | |
| Male (n (%)) | 86 (31.7%) | 462 (24.4%) | 548 (25.3%) | | |
| Female (n (%)) | 185 (68.3%) | 1431 (75.6%) | 1616 (74.7%) | | |
| HIV Positive | 5 (1.9%) | 12 (0.6%) | 17 (0.8%) | 0.052 | 2.09 (0.66, 6.55) |
| Diabetes | 89 (32.8%) | 522 (27.6%) | 611 (28.2%) | 0.07 | NA |
| Urinary Tract Disease | 226 (83.4%) | 1420 (75.0%) | 1646 (76.1%) | 0.003 | 1.43 (1.01, 2.03) |
| Malignancy | 59 (21.8%) | 363 (19.2%) | 422 (19.5%) | 0.31 | NA |
| Mean (range) Duration of Catheterization Prior to CAUTI Onset, in days (Mean) | 7.74 (0-78) | 6.32 (0-124) | 6.50 (0-124) | *0.03* | 0.99 (0.98, 1.01) |
| Urinary Tract Procedure | 26 (9.59%) | 113 (5.97%) | 139 (6.42%) | 0.02 | 1.43 (0.88, 2.32) |
| Mean (range) Charlson Comorbidity Score | 7.73 (0-35) | 6.76 (0-51) | 6.88 (0-51) | 0.001 | 1.03 (0.99, 1.06) |
| Antibiotics Received Prior to CAUTI Onset | 174 (64.2%) | 804 (42.5%) | 978 (45.2%) | <0.0001 | NA |
| Antibiotic received** | | | | | |
| Aminoglycoside | 27 (9.9%) | 73 (3.9%) | 100 (4.6%) | <0.0001 | 5.42 (1.77, 16.55) |
| Cephalosporin, 1st Gen. | 66 (24.4%) | 346 (18.3%) | 412 (19.0%) | 0.02 | 2.34 (1.63, 3.36) |
| Cephalosporin, 3rd Gen. | 23 (8.5%) | 29 (1.5%) | 52 (2.4%) | <0.0001 | 2.89 (0.79, 10.67) |
| Macrolide | 22 (8.1%) | 69 (3.7%) | 91 (4.2%) | 0.001 | 2.39 (1.12, 5.08) |
| Penicillin, 2nd Gen. | 17 (6.3%) | 91 (4.8%) | 108 (5.0%) | 0.30 | NA |
| Penicillin, 4th Gen. | 50 (18.5%) | 173 (9.1%) | 223 (10.3%) | <0.0001 | 2.65 (1.48, 4.76) |
| Vancomycin | 59 (21.8%) | 203 (10.7%) | 262 (12.1%) | <0.0001 | 3.40 (2.26, 5.12) |

CAUTI, catheter-associated urinary tract infection; ESBL, extended-spectrum beta-lactamase; NA, not included in multivariable model.

a Chi-Square test unless otherwise denoted; *t*-test; Fisher’s Exact Test; Wilcoxon-Mann-Whitney Test.

*F* Test for Equality of Variances indicated unequal variance and appropriate p-value was used.

** In the multivariable model, antibiotics were examined as a seven-level categorical variable. Reference category: No antibiotics prior to CAUTI onset.
availability. Lastly, although our definition of CAUTI is consistent with NHSN guidelines of UTI onset >48 hours after catheterization, it is possible that some patients were bacteriuric prior to catheter insertion.

This study provides further evidence that treatment with beta-lactam and non-beta-lactam antibiotics is a risk factor for acquiring ESBL-producing E. coli CAUTI. Urinary tract disease is also identified as a risk factor, independent of antibiotic treatment and length of catheterization. Consistent with other reports, this study found an increase in ESBL prevalence among CAUTI in recent years. Risk factors for ESBL emergence may be different in CAUTI than in non-catheter-associated UTI.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
JTS performed the data analysis and drafted the manuscript. BC contributed to the data analysis and manuscript development. JL programmed the database and contributed to data analysis. EL contributed to the conception and design of the study and manuscript development. All authors reviewed, revised, and approved of the final manuscript.

Received: 26 September 2014 Accepted: 9 December 2014
Published online: 27 December 2014

References
1. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK. NHSN annual update: Antimicrobial-resistant pathogens associated with healthcare-associated infections: Annual summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2006-2007. Infect Control Hosp Epidemiol 2008, 29:996–1011.
2. Ena J, Arjona F, Martínez-Peinado C, Lopez-Perezaguía Md el M, Amador C. Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Urology 2006, 68:1169–1174.
3. Zilberberg MD, Shorr AF. Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000-2009. Infect Control Hosp Epidemiol 2013, 34:940–946.
4. Apte M, Neidell M, Furuya EY, Caplan D, Glied S, Larson E. Using Electronically Available Inpatient Hospital Data for Research. Clin Transl Sci 2011, 4:338–345.
5. Landers T, Apte M, Hyman S, Furuya Y, Glied S, Larson E. A comparison of methods to detect urinary tract infections using electronic data. Jt Comm J Qual Patient Saf 2010, 36:411–417.
6. Azap OK, Arslan H, Serefhanoğlu K, Colakoğlu S, Erdoğan H, Timurkaynak F, Senger SS. Risk factors for extended-spectrum b-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect 2010, 16:147–151.
7. Azap OK, Arslan H, Ergönül O, Colakoğlu S, Erdoğan H, Timurkaynak F, Senger SS. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother 2005, 56:914–918.
8. Calbo E, Romani V, Mencavins M, Gómez L, Vital CG, Quintana S, Vila J, Gatau J. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum b-lactamases. J Antimicrob Chemother 2006, 57:780–783.
9. Yamamoto M, Shimamura K, Matsumoto M, Nakano Y, Tanaka K, Arakawa S, Fujiwara M. Relationship between Urinary Tract Infection Categorization and Pathogens’ Antimicrobial Susceptibilities. Urol Int 2012, 88:198–208.
10. Briongos-Figuero LS, Gómez-Traveso T, Bachiller-Luque P, Domínguez-Gil González M, Gómez-Nieto A, Palacios-Martín T, González-Sagrado M, Duñas-Laita A, Pérez-Castrillón JL. Epidemiology, risk factors, and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacteria. Int J Clin Pract 2012, 66:891–896.